Drug Trial Radar · NCT07914556
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess safety and tolerability at increasing dose levels of 6MW5311 in successive cohorts of participants with MM, AML and CMML in order to estimate the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) or the recommended expansion dose (RED).
Conditions
- AML
- Multiple Myeloma
- CMML
Interventions
6MW5311Biological
A bispecific T cell engager (TCE) antibody: bivalent binding to LILRB4 on tumor cells and monovalent binding to CD3 on T cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities (DLTs)Time frame: From the first dose of Cycle 1 through Day 28 of Cycle 1 (each cycle is 28 days)
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: From first dose through 28 days after the last dose, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.